%PDF-1.3
%
1 0 obj
<<
/Pages 2 0 R
/PageLabels 3 0 R
/Type /Catalog
/Metadata 4 0 R
>>
endobj
5 0 obj
<<
/XPressPrivate <2525446F63756D656E7450726F63657373436F6C6F72733A20426C61636B0A2525456E64436F6D6D656E7473>
/Producer (QuarkXPress\(tm\) 6.5)
/CreationDate (20070723101356)
/Creator (QuarkXPress\(tm\) 6.5)
/ModDate (D:20220412194434+00'00')
>>
endobj
2 0 obj
<<
/Type /Pages
/Kids [6 0 R 7 0 R]
/Count 2
>>
endobj
3 0 obj
<<
/Nums [0 8 0 R]
>>
endobj
4 0 obj
<<
/Type /Metadata
/Subtype /XML
/Length 934
>>
stream
Not for further distribution unless allowed by the License or with the express written permission of Cambridge University Press.
https://doi.org/10.1017/S0317167100006661
https://doi.org/10.1017/S0317167100006661 Published online by Cambridge University Press
2022-04-12T19:44:34+00:00
endstream
endobj
6 0 obj
<<
/Parent 2 0 R
/Type /Page
/MediaBox [0 0 594 783]
/Resources <<
/ProcSet [/PDF /Text]
/Font <<
/F3 9 0 R
/F0 10 0 R
/F1 11 0 R
/F2 12 0 R
/F5 13 0 R
>>
/ExtGState <<
/GS1 14 0 R
/GS0 15 0 R
/GS2 16 0 R
>>
>>
/Contents [17 0 R 18 0 R 19 0 R]
/Annots [20 0 R]
>>
endobj
7 0 obj
<<
/Parent 2 0 R
/Type /Page
/MediaBox [0 0 594 783]
/Resources <<
/ProcSet [/PDF /Text]
/Font <<
/F6 21 0 R
/F0 10 0 R
/F1 11 0 R
/F2 12 0 R
/F5 13 0 R
>>
/ExtGState <<
/GS1 14 0 R
/GS0 15 0 R
/GS2 16 0 R
>>
>>
/Contents [22 0 R 23 0 R 24 0 R]
/Annots [25 0 R]
>>
endobj
8 0 obj
<<
/St 266
/S /D
>>
endobj
9 0 obj
<<
/Widths [250]
/LastChar 32
/FirstChar 32
/Type /Font
/FontDescriptor 26 0 R
/BaseFont /WOIRMT+Times-Bold
/Encoding 27 0 R
/Name /F3
/Subtype /Type1
>>
endobj
10 0 obj
<<
/Widths [250 0 0 0 0 833 0 0 333 333
0 0 250 333 250 0 500 500 500 500
500 500 500 500 500 500 278 278 0 0
0 444 0 722 667 667 722 611 556 722
722 333 389 722 611 889 722 722 556 722
667 556 611 722 0 0 0 0 611 0
0 0 0 0 0 444 500 444 500 444
333 500 500 278 278 500 278 778 500 500
500 500 333 389 278 500 500 722 500 500
444 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
444 444 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 444 444
0 333]
/LastChar 213
/FirstChar 32
/Type /Font
/FontDescriptor 28 0 R
/BaseFont /VLDTSC+Times-Roman
/Encoding 29 0 R
/Name /F0
/Subtype /Type1
>>
endobj
11 0 obj
<<
/Widths [250 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 631 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 713]
/LastChar 181
/FirstChar 32
/Type /Font
/FontDescriptor 30 0 R
/BaseFont /GTEVMG+Symbol
/Encoding 31 0 R
/Name /F1
/Subtype /Type1
>>
endobj
12 0 obj
<<
/Widths [250 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 332 0 0 0
0 0 0 721 0 721 721 666 610 776
0 388 0 0 666 0 721 776 610 0
721 555 666 0 0 0 0 0 0 0
0 0 0 0 0 499 0 443 0 443
332 0 555 277 0 555 0 0 555 499
0 0 443 388 332]
/LastChar 116
/FirstChar 32
/Type /Font
/FontDescriptor 32 0 R
/BaseFont /LGPRQR+Times-Bold
/Encoding 33 0 R
/Name /F2
/Subtype /Type1
>>
endobj
13 0 obj
<<
/Type /Font
/BaseFont /AAADWD+NotoSans
/Subtype /Type0
/Encoding /Identity-H
/DescendantFonts [34 0 R]
/ToUnicode 35 0 R
>>
endobj
14 0 obj
<<
/OP true
/Type /ExtGState
>>
endobj
15 0 obj
<<
/OPM 1
/Type /ExtGState
>>
endobj
16 0 obj
<<
/OP false
/Type /ExtGState
>>
endobj
17 0 obj
<<
/Filter /FlateDecode
/Length 10
>>
stream
x+ |
endstream
endobj
18 0 obj
<<
/Length 10580
>>
stream
/GS0 gs
1 g
0 783 0 0 re
f
/GS1 gs
q
BT
/F0 1 Tf
9 0 0 9 39.696 29.4312 Tm
0 0 0 1 k
(266)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 320.8 604.5035 Tm
0 0 0 1 k
-0.021 Tw
[(The LRRK 2 gene is a very lar)18(ge gene consisting of 51 exons,)]TJ
-1.26315 -1.15789 TD
0.049 Tw
(with pathological mutations reported to date in 10 of the exons.)Tj
0 -1.1579 TD
0.02 Tw
[(The most common mutation is G2019S, located in exon 41. )18(The)]TJ
0 -1.15789 TD
0.009 Tw
[(frequency of this mutation varies among dif)18(ferent ethnic groups,)]TJ
T*
0.073 Tw
(with the highest frequency found in PD patients from Northern)Tj
0 -1.1579 TD
-0.021 Tw
[(Africa, including the )55(Arabic (30%) and )55(Ashkenazy Jewish (18%))]TJ
0 -1.15789 TD
0.15 Tw
(populations. It has been postulated that the founder mutation)Tj
T*
0.108 Tw
((the same one for both populations) occurred over 3,000 years)Tj
0 -1.1579 TD
0.343 Tw
[(ago. )18(This mutation is much less common in the Northern)]TJ
0 -1.15789 TD
0.016 Tw
(European populations. Up to 1% of patients with early onset PD)Tj
T*
0.025 Tw
(carry this gene.)Tj
1.26315 -1.1579 TD
0.059 Tw
(Thus, based on population data, it appears that the two most)Tj
-1.26315 -1.1579 TD
0.013 Tw
(common involved loci in familial and sporadic PD are the genes)Tj
0 -1.15789 TD
0.036 Tw
(for Parkin and LRRK 2. Until very recently)Tj
17.62846 0 TD
-0.0001 Tc
(,)Tj
0.53624 0 Td
0 Tc
(genetic testing was)Tj
-18.1647 -1.1579 TD
0.043 Tw
(only available in research laboratories under research protocols,)Tj
T*
0.121 Tw
(but has now become available as a service in the U.S. Should)Tj
0 -1.15789 TD
0.024 Tw
(testing be routinely available in Canada? Several general issues)Tj
0 -1.1579 TD
0.025 Tw
(need to be considered:)Tj
1.89473 -2.31579 TD
0.218 Tw
(1\) If individuals are confirmed to have a mutated gene,)Tj
0 -1.1579 TD
0.154 Tw
[(treatment remains the same. )18(There is no neuroprotective)]TJ
T*
0.025 Tw
(therapy or impact on management.)Tj
0 -1.15789 TD
0 Tw
(2\))Tj
1.09837 0 TD
0.006 Tw
(Penetrance is decreased in LRRK 2, that is, not everyone)Tj
-1.09837 -1.1579 TD
0.135 Tw
(who has this gene will develop symptoms. )Tj
18.4907 0 TD
0 Tw
(Alternatively)Tj
5.21045 0 TD
(,)Tj
-23.70115 -1.1579 TD
0.323 Tw
(some individuals may be quite elderly before showing)Tj
0 -1.15789 TD
0.222 Tw
(symptoms. )Tj
5.28656 0 TD
(Thus, clinical correlation can be dif)Tj
15.30513 0 TD
(ficult to)Tj
-20.59169 -1.1579 TD
0 Tw
(determine. )Tj
T*
0.019 Tc
0.356 Tw
(3\) Only the more common mutations can be easily)Tj
0 -1.15789 TD
0 Tc
0.179 Tw
(identified. Sequencing of the whole gene to identify less)Tj
T*
0.025 Tw
(common mutations is very expensive and time consuming.)Tj
0 -1.1579 TD
0.019 Tw
[(4\) )55(As these two genetic loci still represent a minority of PD)]TJ
T*
0.025 Tw
[(cases, cost-ef)18(fectiveness of testing would be low)65(.)]TJ
0 -1.15789 TD
0.252 Tw
(4\) Heterozygote carriers of the Parkin mutation are not)Tj
T*
0.372 Tw
[(uncommon. However)40(, significant controversy exists on)]TJ
0 -1.1579 TD
-0.033 Tw
(whether this translates to a predisposition for developing PD)Tj
0 -1.15789 TD
0.025 Tw
((recent evidence suggests not).)Tj
T*
0.081 Tw
(5\) Psychosocial ef)Tj
7.47412 0.00001 TD
(fects of testing in the PD population are)Tj
-7.47412 -1.15791 TD
0 Tw
(unknown.)Tj
-0.63158 -2.31579 TD
0.066 Tw
(The two papers in this issue of the Journal address the issue)Tj
-1.26315 -1.1579 TD
0.035 Tw
(of whether LRRK2 is a cause of PD in the Canadian population)Tj
0 -1.15789 TD
0.005 Tw
[(with emphasis on French Canadians. )55(A)-200(total of 335 patients with)]TJ
T*
0.305 Tw
(PD from Ontario and Quebec were screened; of these, the)Tj
0 -1.1579 TD
0.02 Tc
0.486 Tw
(majority (252) were drawn from the French Canadian)Tj
0 -1.15789 TD
0 Tc
0 Tw
(population.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 351.8098 123.6386 Tm
0 0 0 1 k
(5,6)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 363.1136 120.5034 Tm
0 0 0 1 k
0.115 Tw
(Both papers conclude that the common mutation)Tj
-5.71722 -1.15789 TD
0.009 Tc
0.366 Tw
((G2019S) is not present in this population. Dupre et al)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 551.1996 112.6386 Tm
0 0 0 1 k
(5)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 308.8 98.5034 Tm
0 0 0 1 k
0.139 Tw
(additionally screened exon 31, while Grimes et al)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 506.3749 101.6386 Tm
0 0 0 1 k
(6)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 513.2036 98.5034 Tm
0 0 0 1 k
0.139 Tw
(screened a)Tj
-21.51617 -1.15789 TD
0.069 Tw
(total of seven exons with negative results. Concomitant genetic)Tj
-27.03158 54.42105 TD
0.02 Tc
0.481 Tw
[(Parkinson\325)55(s Disease (PD) is one of the commonest)]TJ
-1.26316 -1.15789 TD
0 Tc
0.033 Tw
[(neurodegenerative disorders, af)18(fecting 1 in 100 individuals over)]TJ
0 -1.1579 TD
0.223 Tw
(the age of 60. Since its original description in the mid-19th)Tj
0 -1.15789 TD
-0.014 Tw
[(century)65(, great strides have been made in the understanding of the)]TJ
T*
0.111 Tw
[(pathology and biochemical abnormalities. )18(The introduction of)]TJ
0 -1.1579 TD
0.147 Tw
[(levodopa for symptomatic treatment in the 1960\325)55(s, resulted in)]TJ
0 -1.15789 TD
0.025 Tw
(significant improvement in motor function and quality of life.)Tj
1.26316 -1.15789 TD
0.098 Tw
[(One of the remaining mysteries is the etiology)65(. Previously)65(,)]TJ
-1.26316 -1.1579 TD
0.04 Tw
(the focus has been on environmental factors and toxins, such as)Tj
0 -1.15789 TD
0.088 Tw
[(viruses, manganese and pesticides. )55(A)-283(variety of factors such as)]TJ
T*
-0.01 Tw
[(living in a rural area, mild head injury)65(, and lack of smoking have)]TJ
0 -1.1579 TD
0.358 Tw
(been reported to increase the risk of PD.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 216.8113 486.6386 Tm
0 0 0 1 k
(1)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 225.7256 483.5035 Tm
0 0 0 1 k
(However)Tj
3.62452 0 TD
-0.0001 Tc
(,)Tj
0.85818 0 Td
0 Tc
(with)Tj
-24.03276 -1.1579 TD
0.16 Tw
[(increasing life expectancy)65(, it has become evident that at least)]TJ
0 -1.15789 TD
0.02 Tw
(10% of patients with PD have similarly af)Tj
16.92287 0 TD
(fected relatives. Over)Tj
-16.92287 -1.1579 TD
0.102 Tw
(the past 2 decades, research has shifted to the identification of)Tj
T*
0.025 Tw
(genetic factors.)Tj
1.26316 -1.15789 TD
0.011 Tw
(The first major breakthrough came in 1997 with the report of)Tj
-1.26316 -1.1579 TD
0.0198 Tc
(a)Tj
1.17313 0 Td
0.02 Tc
0.439 Tw
[(lar)18(ge multi-generation family with Parkinsonism, and)]TJ
-1.17313 -1.1579 TD
0 Tc
0.227 Tw
(subsequent isolation of the responsible gene \(now known as)Tj
0 -1.15789 TD
0.04 Tw
(SNCA\) coding for )Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
9.5 0 0 9.5 113.6992 395.5035 Tm
0 0 0 1 k
Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 123.2301 395.5035 Tm
0 0 0 1 k
(-synuclein.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 165.173 398.6386 Tm
0 0 0 1 k
(2)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 170.8971 395.5035 Tm
0 0 0 1 k
0.04 Tw
(This was a novel finding, and)Tj
-13.77864 -1.1579 TD
0.008 Tc
0.367 Tw
(changed the nomenclature of the Parkinsonian conditions,)Tj
T*
0.02 Tc
0.568 Tw
[(leading to PD being identified as a synucleinopathy)65(.)]TJ
0 -1.15789 TD
0 Tc
0.155 Tw
(\(Synucleinopathies now encompass both sporadic and SCNA-)Tj
0 -1.1579 TD
0.025 Tw
(PD, Lewy body disease, and multi-system atrophy\).)Tj
1.26316 -1.1579 TD
0.173 Tw
(Over the past ten years, eight Mendelian genes have been)Tj
-1.26316 -1.15789 TD
0.358 Tw
(identified to cause Parkinsonism. )Tj
14.93718 0 TD
(These have been labeled)Tj
-14.93718 -1.1579 TD
0.01 Tw
[(P)92(ARK 1-9 \(P)92(ARK 4 is homologous to P)91(ARK 1\).)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 224.7029 321.6386 Tm
0 0 0 1 k
(3)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 230.308 318.5035 Tm
0 0 0 1 k
0.01 Tw
[(Parkin \(P)92(ARK)]TJ
-20.03242 -1.1579 TD
0.127 Tw
(2\), inherited as an autosomal recessive trait, appears to be the)Tj
0 -1.15789 TD
-0.031 Tw
(most common cause of early onset of PD, occurring in up to 20%)Tj
T*
0.32 Tw
[(of cases. )18(The protein is thought to be involved in protein)]TJ
0 -1.1579 TD
0.001 Tc
0.374 Tw
[(degradation in the ubiquitin proteosomal system. P)92(ARK 6)]TJ
T*
0 Tc
0.367 Tw
((PINK1) and 7 (DJ1 gene), both autosomal recessive, are)Tj
0 -1.15789 TD
0.171 Tw
(uncommon; the gene products may be involved in stabilizing)Tj
T*
0.02 Tc
0.74 Tw
(mitochondrial function. Initial reports suggested that)Tj
0 -1.1579 TD
0 Tc
0.221 Tw
(heterozygote carriers of these recessive mutations may be at)Tj
0 -1.15789 TD
-0.03 Tw
[(higher risk for developing \322typical\323 PD in later life. )18(This remains)]TJ
T*
0.002 Tw
(controversial and recent reappraisal of the data suggests that this)Tj
0 -1.1579 TD
0.025 Tw
(is not the case.)Tj
1.26316 -1.15789 TD
0.137 Tw
[(In 2004, the LRRK 2 \(P)92(ARK 8\) gene was discovered, and)]TJ
-1.26316 -1.15789 TD
0.375 Tw
(mutations at this locus shown to be a common cause of)Tj
0 -1.1579 TD
0.025 Tw
(Parkinsonism both is familial and sporadic cases.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 228.4656 167.6386 Tm
0 0 0 1 k
(4)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 52 153.5034 Tm
0 0 0 1 k
0.033 Tw
(The LRRK 2 mutations can cause what appears to be typical)Tj
-1.26316 -1.15789 TD
0.145 Tw
[(PD with late onset, and responsiveness to levolopa. However)40(,)]TJ
0 -1.1579 TD
0.025 Tw
[(even in the same family)65(, manifestations can be variable as some)]TJ
0 -1.15789 TD
0.023 Tw
(individuals have very late onset and little progression; in others,)Tj
T*
0.187 Tw
(the gene is non penetrant. Occasionally)Tj
16.58638 0.00001 TD
-0.0001 Tc
(,)Tj
0.68689 0 Td
0 Tc
(dementia or atypical)Tj
-17.27327 -1.1579 TD
0.107 Tw
[(Parkinsonism may be seen. On autopsy)65(, pathology can also be)]TJ
0 -1.15789 TD
0 Tw
(variable.)Tj
ET
4 w
0 0 0 1 K
160.024 750 m
554.024 750 l
S
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
22 0 0 22 160.024 720 Tm
0 0 0 1 k
0.001 Tc
0.025 Tw
[(The Genetics of Parkinson Disease: )19(T)91(o)]TJ
0 -1.18181 TD
[(T)92(est or)-257(Not to )19(T)92(est)]TJ
ET
1 w
0 0 0 1 K
40.024 648.4999 m
554.024 648.4999 l
S
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 405.8986 667 Tm
0 0 0 1 k
0.025 Tw
(Can. J. Neurol. Sci. 2007; 34: 266-267)Tj
ET
1 w
0 0 0 1 K
39.524 751.454 m
162.524 751.454 l
S
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
9 0 0 9 40.024 740.7996 Tm
0 0 0 1 k
0.0013 Tc
(E)Tj
0.66727 0.00001 TD
0.001 Tc
[(DIT)19(ORIAL)]TJ
/F3 1 Tf
1 0 0 1 -1000 1783 Tm
1 g
-0.25 Tc
( )Tj
ET
Q
endstream
endobj
19 0 obj
<<
/Filter /FlateDecode
/Length 237
>>
stream
xmK1["T$zI^K][Bok} 4&MNX;>r}fI(+|YIkr1V>DAͧQmjVVz ӻGzikSK3ԞKM+x2%-rjUq^$hcqd6t[/nhM;A)Xi
}-W
7y
endstream
endobj
20 0 obj
<<
/Type /Annot
/Subtype /Link
/Rect [7.7999997 14.264648 133.62 22.189453]
/Border [0 0 0]
/A 36 0 R
>>
endobj
21 0 obj
<<
/Widths [250 0 0 0 0 0 0 0 0 0
0 0 250 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 611 0 667 0 0 0 0
0 0 0 0 0 0 0 722 0 0
0 500 0 0 0 0 0 0 0 0
0 0 0 0 0 500 500 444 0 444
0 500 500 0 0 444 278 0 500 500
0 0 389 389 278 500 0 667 0 444]
/LastChar 121
/FirstChar 32
/Type /Font
/FontDescriptor 37 0 R
/BaseFont /QCEAPS+Times-Italic
/Encoding 38 0 R
/Name /F6
/Subtype /Type1
>>
endobj
22 0 obj
<<
/Filter /FlateDecode
/Length 10
>>
stream
x+ |
endstream
endobj
23 0 obj
<<
/Length 4558
>>
stream
/GS0 gs
1 g
0 783 0 0 re
f
q
/GS1 gs
0 0 0 0 k
39.024 726 516 30 re
f
Q
/GS1 gs
q
BT
/F0 1 Tf
9 0 0 9 308.5412 749.8455 Tm
0 0 0 1 k
0.025 Tw
[(LE JOURNAL)-238(CANADIEN DES SCIENCES NEUROLOGIQUES)]TJ
-29.94636 -80.04603 TD
-0.0001 Tc
(THE)Tj
2.21865 0 Td
0 Tc
[(CANADIAN JOURNAL)-238(OF NEUROLOGICAL)-238(SCIENCES)-28798(267)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 40.024 717.0228 Tm
0 0 0 1 k
0.375 Tw
(screening in 224 normal controls also did not reveal any)Tj
0 -1.15789 TD
0.014 Tc
0.361 Tw
[(mutations. )18(Thus, it appears that in this population, even)]TJ
T*
0 Tc
-0.004 Tw
(excluding the factors listed above, testing for LRRK 2 mutations)Tj
0 -1.1579 TD
0.025 Tw
(would not be a fruitful diagnostic exercise.)Tj
1.26316 -1.15789 TD
0.115 Tw
(Is there a place for any genetic testing? In individuals with)Tj
-1.26316 -1.15789 TD
0.163 Tw
(atypical symptoms, for example cerebellar ataxia, or a family)Tj
0 -1.1579 TD
0.229 Tw
[(history)65(, it is important to remember the autosomal dominant)]TJ
0 -1.15789 TD
0.122 Tw
[(triplet repeat conditions that can mimic PD. )18(These include the)]TJ
T*
0.266 Tw
(spinocerebellar ataxias types 2, 3, 6 and 17, and late onset)Tj
0 -1.1579 TD
0.269 Tw
(Huntington disease. Genetic testing is readily available, and)Tj
0 -1.15789 TD
0.025 Tw
(should be considered both for diagnosis, and family counseling. )Tj
1.26316 -1.15789 TD
0.355 Tw
(In conclusion, the search for etiological factors for PD)Tj
-1.26316 -1.1579 TD
0.102 Tw
(continues. In a minority of patients, there may be a significant)Tj
0 -1.15789 TD
0.003 Tw
[(genetic cause. In the majority)65(, the etiology continues to likely be)]TJ
T*
0.064 Tw
(multi-factorial, due to a genetic predisposition and one or more)Tj
0 -1.1579 TD
0.004 Tc
0.371 Tw
(as yet unidentified environmental factors. Further research)Tj
0 -1.15789 TD
0 Tc
-0.035 Tw
(hopefully will lead to a better understanding of pathogenesis, and)Tj
T*
0.143 Tw
[(to a preventative or neuroprotective therapy)65(. In the meantime,)]TJ
0 -1.1579 TD
0.19 Tw
(genetic testing and screening for PD associated genes should)Tj
0 -1.15789 TD
0.025 Tw
(remain in the research laboratory)Tj
13.24942 0.00001 TD
(.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F6 1 Tf
9.5 0 0 9.5 204.3359 475.0228 Tm
0 0 0 1 k
0.025 Tw
(Oksana Suchowersky)Tj
1.8208 -1.1579 TD
0.007 Tw
[(Calgary)55(, Alberta)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
9.5 0 0 9.5 309.16 717.0228 Tm
0 0 0 1 k
(R)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
7.125 0 0 7.125 316.0183 717.0228 Tm
0 0 0 1 k
0.0011 Tc
(E)Tj
0.66706 -0.00001 TD
0.001 Tc
(FERENCES)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
8.5 0 0 8.5 309.16 704.0228 Tm
0 0 0 1 k
(1)Tj
0.5 -0.00001 TD
0.089 Tw
[(.)-662(Semchuk KM, Love EJ, Lee RG. Parkinson\325)55(s disease: a test of the)]TJ
2.55882 -1.05882 TD
0.012 Tc
0.362 Tw
[(multifactorial etiologic hypothesis. Neurology)65(. 1993;43(6):)]TJ
T*
0 Tc
0 Tw
[(1)37(173-80.)]TJ
-3.05882 -1.05882 TD
0.001 Tw
[(2.)-662(Polymeropoulos MH, lavedan C, Leroyt E, Ide SE, Dehejia )55(A, Dutra)]TJ
3.05882 -1.05882 TD
0.048 Tw
(A, et al. Mutation in the )Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
8.5 0 0 8.5 421.1862 668.0228 Tm
0 0 0 1 k
(a)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
8.5 0 0 8.5 426.5485 668.0228 Tm
0 0 0 1 k
0.048 Tw
(-synuclein gene identified in families)Tj
-10.75159 -1.05882 TD
0.025 Tw
[(with Parkinson\325)55(s disease. Science. 1997;276:2045-7.)]TJ
-3.05882 -1.05882 TD
0.208 Tw
[(3.)-662(Klein C, Schlossmacher MG. )18(The genetics of Parkinson disease:)]TJ
3.05882 -1.05882 TD
-0.002 Tw
(implications for neurological care. Nat Clin Prac Neurol. March)Tj
(2)'
0.49995 -0.00001 TD
0 Tw
(006;2:136-46.)Tj
-3.55878 -1.05882 TD
0.068 Tw
[(4.)-662(Zimprich )55(A, Bisup S, Leitner P)111(, Lichtner P)111(, Farrer M, Lincoln S, et)]TJ
3.05882 -1.05882 TD
0.02 Tc
0.849 Tw
(al. Mutations in LRRK2 cause autosomal-dominant)Tj
T*
0.016 Tc
0.359 Tw
[(parkinsonism with pleomorphic pathology)65(. Neuron. 2004;)]TJ
T*
0 Tc
0 Tw
(44:601-7.)Tj
-3.05882 -1.05882 TD
-0.002 Tw
[(5.)-662(Dupr\216 N, Rivi\217re J, Myers RM, Provencher P)111(, Pourcher E, Emond F)80(,)]TJ
3.05882 -1.05882 TD
0.117 Tw
[(Rouleau GA. LRRK2 is not a significant cause of Parkinson\325)55(s)]TJ
T*
0.025 Tw
(disease in French-Canadians. Can J Neurol Sci. 2007;34:333-5.)Tj
-3.05882 -1.05882 TD
(6)Tj
0.5 -0.00001 TD
0.137 Tw
[(.)-662(Grimes DA, Racacho L, Han F)80(, Panisset M, Bulman DE. LLRK2)]TJ
2.55882 -1.05882 TD
0.309 Tw
[(Screening in a Canadian Parkinson\325)55(s disease cohort. Can J)]TJ
T*
0.025 Tw
(Neurol Sci. 2007;34:336-8.)Tj
ET
Q
endstream
endobj
24 0 obj
<<
/Filter /FlateDecode
/Length 237
>>
stream
xmK1["T$zI^K][Bok} 4&MNX;>r}fI(+|YIkr1V>DAͧQmjVVz ӻGzikSK3ԞKM+x2%-rjUq^$hcqd6t[/nhM;A)Xi
}-W
7y
endstream
endobj
25 0 obj
<<
/Type /Annot
/Subtype /Link
/Rect [7.7999997 14.264648 133.62 22.189453]
/Border [0 0 0]
/A 39 0 R
>>
endobj
26 0 obj
<<
/FontFile3 40 0 R
/XHeight 921
/StemV 25
/Type /FontDescriptor
/Ascent 912
/FontName /WOIRMT+Times-Bold
/Descent -203
/Flags 262178
/FontBBox [-168 -218 998 934]
/StemH 0
/ItalicAngle 0
/CapHeight 676
>>
endobj
27 0 obj
<<
/Differences [32 /space]
/BaseEncoding /MacRomanEncoding
/Type /Encoding
>>
endobj
28 0 obj
<<
/FontFile3 41 0 R
/XHeight 677
/StemV 84
/Type /FontDescriptor
/Ascent 684
/FontName /VLDTSC+Times-Roman
/Descent -215
/Flags 34
/FontBBox [-168 -218 1000 899]
/StemH 0
/ItalicAngle 0
/CapHeight 662
>>
endobj
29 0 obj
<<
/Differences [32 /space 37 /percent 40 /parenleft /parenright 44 /comma /hyphen
/period 48 /zero /one /two /three /four /five /six /seven
/eight /nine /colon /semicolon 63 /question 65 /A /B /C
/D /E /F /G /H /I /J /K /L /M
/N /O /P /Q /R /S /T /U 90 /Z
97 /a /b /c /d /e /f /g /h /i
/j /k /l /m /n /o /p /q /r /s
/t /u /v /w /x /y /z 142 /eacute /egrave
210 /quotedblleft /quotedblright 213 /quoteright]
/BaseEncoding /MacRomanEncoding
/Type /Encoding
>>
endobj
30 0 obj
<<
/FontFile3 42 0 R
/XHeight 684
/StemV 41
/Type /FontDescriptor
/Ascent 921
/FontName /GTEVMG+Symbol
/Descent -223
/Flags 4
/FontBBox [-180 -292 1090 1005]
/StemH 0
/ItalicAngle 0
/CapHeight 671
>>
endobj
31 0 obj
<<
/Differences [32 /space 97 /alpha 181 /proportional]
/BaseEncoding /MacRomanEncoding
/Type /Encoding
>>
endobj
32 0 obj
<<
/FontFile3 43 0 R
/XHeight 921
/StemV 25
/Type /FontDescriptor
/Ascent 912
/FontName /LGPRQR+Times-Bold
/Descent -203
/Flags 262178
/FontBBox [-168 -218 998 934]
/StemH 0
/ItalicAngle 0
/CapHeight 676
>>
endobj
33 0 obj
<<
/Differences [32 /space 58 /colon 65 /A 67 /C /D /E
/F /G 73 /I 76 /L 78 /N /O /P
82 /R /S /T 97 /a 99 /c 101 /e
/f 104 /h /i 107 /k 110 /n /o 114
/r /s /t]
/BaseEncoding /MacRomanEncoding
/Type /Encoding
>>
endobj
34 0 obj
<<
/Type /Font
/Subtype /CIDFontType2
/BaseFont /AAADWD+NotoSans
/CIDSystemInfo 44 0 R
/FontDescriptor 45 0 R
/W [0 [600]
3 [260]
17 [268 372 572 572]
22 [572]
25 [572 572]
29 [268]
38 [632]
51 [605]
54 [549]
56 [731]
68 [561 615]
71 [615 564]
74 [615 618 258]
79 [258 935 618 605 615]
85 [413 479 361 618 508]
92 [510]
]
/CIDToGIDMap 46 0 R
>>
endobj
35 0 obj
<<
/Filter /FlateDecode
/Length 327
>>
stream
x]j0^,]aqEf\Ct/|9/s&qf